- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03122639
Endothelial Function in Obstructive Sleep Apnea
Vascular Endothelial Activation in Obstructive Sleep Apnea
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
To address the hypothesis, the investigators seek to determine whether statins prevent endothelial dysfunction in OSA by restoring complement inhibition. The preliminary data indicate that the expression of CD59 on the EC surface is preserved in OSA patients who are receiving statins and that statins prevent CD59 internalization and MAC deposition in IH leading to reduced inflammation. The study proposes to determine whether statins restore endothelial protection against complement activity in OSA patients using double-blind placebo-controlled parallel group randomized study design. The hypothesis: The proportion of CD59 on the EC surface is increased while MAC deposition is decreased after 4 weeks of atorvastatin 10 mg daily compared with placebo in OSA patients who adhere with CPAP or do not adhere with CPAP.
The proposed studies may advance our understanding of vascular dysfunction in OSA and provide the basis for large, long-term clinical trials of novel therapeutic strategies, such as addition of statins to the standard CPAP therapy, for preventing and/or reversing vascular risk in OSA.
Study Type
Enrollment (Actual)
Phase
- Early Phase 1
Contacts and Locations
Study Locations
-
-
New York
-
New York, New York, United States, 10032
- Columbia University Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Patients aged ≥18 years with newly diagnosed obstructive sleep apnea (OSA) who were never treated with CPAP. OSA is defined as apnea-hypopnea index (AHI) ≥5 events/hour of sleep.
Exclusion Criteria:
- A history of coronary artery disease, heart failure, stroke, diabetes, malignancy, chronic pulmonary, kidney or rheumatologic disease, muscle pain/fatigue, smoking within the past 5 years, regular use of any medications.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Treatment
OSA patients who adhered or did not adhere with CPAP will be randomized 1:1 to treatment (atorvastatin 10 mg daily) or control group (placebo).
|
Atorvastatin 10 mg daily for 28 days will be randomly allocated to OSA patients regardless of adherence with CPAP.
CPAP is a standard of care for OSA and will be prescribed by care providers not associated with this study based on clinical indications.
The investigators will have no role in prescribing CPAP.
Atorvastatin and placebo will be encapsulated to appear identical and dispensed by the research pharmacy.
Other Names:
|
Placebo Comparator: Control
OSA patients who adhered or did not adhere with CPAP will be randomized 1:1 to treatment (atorvastatin 10 mg daily) or control group (placebo).
|
Placebo daily for 28 days will be randomly allocated to OSA patients regardless of adherence with CPAP.
CPAP is a standard of care for OSA and will be prescribed by care providers not associated with this study based on clinical indications.
The investigators will have no role in prescribing CPAP.
Atorvastatin and placebo will be encapsulated to appear identical and dispensed by the research pharmacy.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in proportion of CD59 on the endothelial cell (EC) surface (the percent [%] of the total cellular CD59 protein that is expressed on the endothelial cell surface).
Time Frame: Up to 28 days
|
Outcome 1 will be assessed before and after 4 weeks of atorvastatin or placebo.
Each patient 28-day follow-up value will be compared with baseline value.
There is no reference range for this marker of complement regulation.
The percent of total CD59 located on the EC plasma membrane will be quantified using immunofluorescence and confocal microscopy.
This is a single outcome measure.
The unit is percent (%) of the total cellular CD59 protein that is expressed on the endothelial cell surface.
|
Up to 28 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
MAC deposition on EC surface (measurement unit is fluorescent area quantified as micrometer square).
Time Frame: Up to 28 days
|
Outcome 2 will be assessed before and after 4 weeks of atorvastatin or placebo.
Each patient 28-day follow-up value will be compared with baseline value.
This is a single outcome measure.
There is no reference range for this marker of complement regulation.
MAC deposition on the EC plasma membrane will be quantified using immunofluorescence and confocal microscopy and expressed as the fluorescent area in micrometer square.
|
Up to 28 days
|
ORP1L (late endosome protein) and VAPB (endoplasmic reticulum protein) interaction (measurement unit is fluorescent area quantified as micrometer square).
Time Frame: 1 day
|
Outcome 3 will be assessed at baseline between healthy control and OSA group.
|
1 day
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Sanja Jelic, MD, Columbia University
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Nervous System Diseases
- Respiratory Tract Diseases
- Respiration Disorders
- Sleep Disorders, Intrinsic
- Dyssomnias
- Sleep Wake Disorders
- Signs and Symptoms, Respiratory
- Sleep Apnea Syndromes
- Sleep Apnea, Obstructive
- Apnea
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antimetabolites
- Anticholesteremic Agents
- Hypolipidemic Agents
- Lipid Regulating Agents
- Hydroxymethylglutaryl-CoA Reductase Inhibitors
- Atorvastatin
Other Study ID Numbers
- AAAR0444
- 2R01HL106041-06A1 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Obstructive Sleep Apnea of Adult
-
Cryosa, Inc.Active, not recruitingObstructive Sleep Apnea of AdultPanama, Paraguay
-
State Key Laboratory of Respiratory DiseaseCompletedObstructive Sleep Apnea of AdultChina
-
Somnics, Inc.UnknownObstructive Sleep Apnea of AdultTaiwan
-
Northwestern UniversitySibel Health Inc.Completed
-
Arizona State UniversityMayo Clinic; National Institute of Nursing Research (NINR)CompletedObstructive Sleep Apnea of AdultUnited States
-
Nyxoah S.A.Nyxoah Pty. Ltd.Not yet recruitingObstructive Sleep Apnea of AdultAustralia
-
Assiut UniversityUnknownObstructive Sleep Apnea of AdultEgypt
-
Cryosa, Inc.RecruitingObstructive Sleep Apnea of AdultPanama
-
Idorsia Pharmaceuticals Ltd.CompletedObstructive Sleep Apnea of AdultGermany
-
Essam FathiCompletedObstructive Sleep Apnea of AdultEgypt
Clinical Trials on Atorvastatin 10mg
-
Organon and CoCompleted
-
GlaxoSmithKlineCompletedDiabetes Mellitus, Type 2Korea, Republic of, Malaysia, Philippines, Thailand, Russian Federation, Mexico
-
Daewon Pharmaceutical Co., Ltd.CompletedHypercholesterolemia, DyslipidemiaKorea, Republic of
-
Zhejiang Hisun Pharmaceutical Co. Ltd.Unknown
-
Samsung Medical CenterNot yet recruiting
-
Yooyoung Pharmaceutical Co., Ltd.CompletedCombined DyslipidemiaKorea, Republic of
-
GlaxoSmithKlineCompletedDyslipidemias | DyslipidaemiasUnited States
-
Sang Hak LeeUnknownMixed HyperlipidemiaKorea, Republic of
-
National Cardiovascular Center Harapan Kita Hospital...CompletedMyocardial Edema
-
Prof. Stephen LeePfizer; Queen Mary Hospital, Hong KongCompletedCoronary Disease | Hydroxymethylglutaryl-CoA Reductase Inhibitors | Ultrasonography, InterventionalChina